The cancer registry as an ally in monitoring treatment effectiveness

Costa, F. A.; Ramos, C.; Murteira, R.; Almodovar, T.; Passos-Coelho, J. L.; Carvalho, M. I.; Costa, L.; Brito, M. J.; Ramos, S.; Ferreira, M.; Miranda, A. C.

Publication

The cancer registry as an ally in monitoring treatment effectiveness

2019-01Journal article

dc.contributor.author	Costa, F. A.
dc.contributor.author	Ramos, C.
dc.contributor.author	Murteira, R.
dc.contributor.author	Almodovar, T.
dc.contributor.author	Passos-Coelho, J. L.
dc.contributor.author	Carvalho, M. I.
dc.contributor.author	Costa, L.
dc.contributor.author	Brito, M. J.
dc.contributor.author	Ramos, S.
dc.contributor.author	Ferreira, M.
dc.contributor.author	Miranda, A. C.
dc.date.accessioned	2019-11-19T15:51:36Z
dc.date.available	2019-11-19T15:51:36Z
dc.date.issued	2019-01
dc.description	This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	pt_PT
dc.description.abstract	OBJECTIVE: To evaluate if the cancer registry database can be used to monitor treatment effectiveness using nivolumab treatment of non-small cell lung cancer (NSCLC) as an example. METHOD: An observational inception cohort was used, where all registered cases of NSCLC with authorisation to initiate treatment with nivolumab were monitored retrospectively to evaluate disease characteristics and response to prior treatments. Current exposure to nivolumab was prospectively characterised and treatment outcomes classified based on the clinical information registered in the patient medical record. The main outcome measure used to assess treatment effectiveness was overall survival (OS). Secondary outcomes considered were progression free survival (PFS) as a measure of effectiveness and occurrence of Adverse Drug Reaction (ADRs) as a measure of safety. Data were analysed using SPSS, version 24. RESULTS: A total of 115 patients received treatment with nivolumab for NSCLC, between November 1st 2015 and July 31st 2016, and were registered in the database. The majority were non-squamous type (n=107). The median OS was 11.4 months {CI95%: 11.1-11.7}, with a 1-year survival of 44%, in line with clinical trial data. Median PFS was 5.4 months {CI95%: 2.8-7.9}. Treatment was discontinued in 82 cases, most frequently due to disease progression. There were 38 cases of ADRs documented in the patient medical chart, 21 of which led to treatment discontinuation. CONCLUSION: The analysed data suggest that the cancer registry is a powerful tool to monitor treatment effectiveness, although considerable investment is needed to improve the medical culture of recording treatment exposure, particularly documentation of ADRs.	pt_PT
dc.description.version	info:eu-repo/semantics/publishedVersion	pt_PT
dc.identifier.citation	F.A. Costa, C. Ramos, R. Murteira, T. Almodovar, J.L. Passos-Coelho, M.I. Carvalho, L. Costa, M.J. Brito, S. Ramos, M. Ferreira, A.C. Miranda, The cancer registry as an ally in monitoring treatment effectiveness, Pulmonology, Volume 25, Issue 1, 2019, Pages 3-8, ISSN 2531-0437, https://doi.org/10.1016/j.pulmoe.2018.05.007	pt_PT
dc.identifier.doi	10.1016/j.pulmoe.2018.05.007	pt_PT
dc.identifier.issn	2531-0437
dc.identifier.uri	http://hdl.handle.net/10400.26/30214
dc.language.iso	eng	pt_PT
dc.peerreviewed	yes	pt_PT
dc.publisher	Elsevier	pt_PT
dc.relation.publisherversion	https://doi.org/10.1016/j.pulmoe.2018.05.007	pt_PT
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/	pt_PT
dc.subject	Drug-related side effects and adverse reactions	pt_PT
dc.subject	Immunotherapy	pt_PT
dc.subject	Lung neoplasms	pt_PT
dc.subject	Registries	pt_PT
dc.subject	Survival analysis	pt_PT
dc.subject	Treatment effectiveness	pt_PT
dc.title	The cancer registry as an ally in monitoring treatment effectiveness	pt_PT
dc.type	journal article
dspace.entity.type	Publication
oaire.citation.endPage	8	pt_PT
oaire.citation.startPage	3	pt_PT
oaire.citation.title	Pulmonology	pt_PT
oaire.citation.volume	25(1)	pt_PT
rcaap.rights	openAccess	pt_PT
rcaap.type	article	pt_PT